Why Your State, Not D.C., Should Be Making This Call

Can a patient in a state that bans abortion get abortion pills after a video visit and a delivery through the mail? Under a federal rule written in Washington, mifepristone can be prescribed by telehealth and mailed or dispensed by retail pharmacies. That is the call at the center of a fight now moving through the Fifth Circuit, with the Supreme Court already involved. Louisiana says the federal rule undercuts its abortion ban. The Food and Drug Administration, defended in court by the Trump Justice Department, says the state has no standing to challenge it.

What is happening

In 2023 the FDA eliminated the requirement that mifepristone be dispensed in person, according to KFF's timeline of the case. Louisiana sued the agency in October 2025, alleging violations of the Administrative Procedure Act and the Comstock Act. In April 2026 a federal district court in Louisiana paused the case for six months so the FDA could continue a safety review it announced in September 2025.

Then the case moved fast. On May 1, a Fifth Circuit panel granted Louisiana's request and reinstated the in-person requirement, Goodwin Law reported. On May 14 the Supreme Court stayed that order in an unsigned decision that left the current rules in place, Jurist reported. Justice Clarence Thomas dissented, arguing the shipments violate the Comstock Act. Justice Samuel Alito dissented too, writing that the mail allowance is "the perpetration of a scheme to undermine" the Dobbs decision, according to Goodwin's summary of the dissents.

On September 9, a Fifth Circuit panel heard arguments in the appeal. Louisiana told the judges it sees about 1,000 mailed-pill abortions a month in the state, Courthouse News reported. On September 30, Louisiana, Alabama and Arkansas went further. They filed a complaint directly at the Supreme Court against California, Massachusetts and New York, and a separate federal suit in Louisiana naming 30 doctors, telehealth companies and nonprofits, according to Stateline.

What is getting less attention

The fight is not only federal versus state. It is also state versus state. Stateline reports that 22 states plus the District of Columbia have passed "shield laws" that block out-of-state investigations and prosecutions of providers who prescribe abortion pills to patients elsewhere. Hoodline reports that California's governor and New York's governor each refused Louisiana's extradition requests for doctors Louisiana has charged. Those are charges, not findings of guilt.

Notably, the federal government's own lawyer pointed at those state laws. Autonomy News reported that Justice Department attorney Daniel Winik told the Fifth Circuit the answer is "the shield laws enacted by other states," not the FDA's modification. We have not seen a hearing transcript, so this account rests on that outlet's reporting.

The FDA's review, meanwhile, remains unfinished. Medical Daily reports the agency had given no completion date as of its latest report. It also reports that Senate Health Committee Republicans said in an August 27 report that the three approved manufacturers could not show how they ensure prescribers follow safety rules.

The other side

Law Commentary reports that the FDA continues to describe mifepristone as safe and effective when used according to its approved conditions. The agency and the manufacturers argue Louisiana's alleged injuries depend on the independent choices of patients and out-of-state providers.

Judges pressed both sides. Courthouse News reported that Judge Priscilla Richman said at the hearing she was having trouble finding anywhere in the record that the FDA approved mailing the drug into states where it is unlawful, and that Judge Stephen Higginson suggested Louisiana was effectively asking the federal government to help enforce a state criminal law. In 2024 the Supreme Court unanimously held in FDA v. Alliance for Hippocratic Medicine that anti-abortion doctors lacked standing, Law Commentary noted. No ruling has been issued from the September 9 hearing.

Our Take

This section is opinion.

We think the call belongs to the states, and we mean that consistently. After Dobbs, the question of whether abortion is lawful was returned to the people of each state. A federal agency's national dispensing rule, and a New York statute that tells Louisiana its laws cannot reach a prescriber, both land on the same place: a Louisiana law that Louisianans passed, that cannot be fully enforced inside Louisiana. In our view, a state's ban should be enforceable within its own borders, and a state that wants a different policy should be free to have one for its own residents. We are pro-life, and we say so plainly.

That principle cuts in uncomfortable directions, and we should name them. Louisiana's own case asks federal judges to change a national rule, and Thomas's Comstock Act reading would be a federal answer too. Opponents argue such routes would restrict access in all fifty states. A truly states-first approach would not need Washington to win it.

We also think the administration deserves pointed questions. Its lawyers are defending a rule its own FDA says it is still reviewing, and no end date had been announced in the latest reporting we found. If voters sent this administration to Washington partly to take federal agencies out of people's business, then a clear answer from the FDA on whether its rule was meant to override state law is overdue. Whatever the courts decide, the legitimate place for this fight is the statehouse and the ballot box, not a regulator's guidance document.